**Brand Name:** Activase/TNKase **Generic:** alteplase/tenecteplase

Type: enzyme

**Year Accepted/Phase:** 

Activase:

AMI: November 1987

Acute Ischemic Stroke: 1996 Pulmonary Embolism: 1990

TNKase: 2000

#### Mechanism:

Tocilizumab is a monoclonal antibody that targets the interleukin-6 receptor (IL-6R), reducing inflammation and modifying the immune response in various inflammatory diseases.

**Chemical Structure: N/A** 

### Indication:

Both alteplase and tenecteplase are tissue plasminogen activators (tPAs) that convert plasminogen to plasmin, the major enzyme responsible for clot breakdown.

#### Clinical trials:

#### **Acute Myocardial Infarction (AMI)**

**GUSTO-I Trial (Activase)** 

Pubmed: https://pubmed.ncbi.nlm.nih.gov/8822974

**Purpose:** Compare the efficacy of alteplase (Activase) with other thrombolytics in

patients with AMI.

**Dates:** Conducted in the early 1990s, with results published in 1993. **Results:** Alteplase was found to be effective in reducing mortality in AMI

patients.

#### ASSENT-2 Trial (TNKase)

**Pubmed:** https://pubmed.ncbi.nlm.nih.gov/10475182/

Purpose: Compare the efficacy and safety of tenecteplase (TNKase) with

alteplase in patients with AMI.

**Dates:** Conducted between 1997 and 1999, with results published in 2000. **Results:** Tenecteplase was found to be as effective as alteplase but with a

simpler administration protocol.

# Acute Ischemic Stroke NINDS Trial (Activase)

Pubmed: https://pubmed.ncbi.nlm.nih.gov/7477192/

Purpose: Evaluate the efficacy of alteplase in the treatment of acute ischemic

stroke.

Dates: Conducted in the mid-1990s, with results published in 1995.

Results: Alteplase significantly improved clinical outcomes when administered

within 3 hours of stroke onset.

## **Pulmonary Embolism**

**Various Trials (Activase)** 

**Purpose:** Assess the efficacy of alteplase in the treatment of acute massive pulmonary embolism.

Dates: Various trials conducted in the 1990s and 2000s.

Results: Alteplase was effective in rapidly resolving pulmonary emboli and

improving hemodynamics.